Loading…

Browse All Grants

20,252 grants found

Filters
Reset

Showing 2,6012,620 of 20,252 grants

Active OTHER RESEARCH-RELATED
Educational Pathways for Cancer Research (EPCR)
NATIONAL CANCER INSTITUTE Indiana University Indianapolis United States 2023 – 2028

The aim of Educational Pathways for Cancer Research (EPCR) at the Indiana University Simon Comprehensive Cancer Center (IUSCCC) and the Indiana University Bloomington (IUB) School...

$3.93M
USD
Active RESEARCH CENTERS
Research Project 1: Diffuse Midline Glioma
NATIONAL CANCER INSTITUTE Dana-Farber Cancer Inst United States 2023 – 2028

Project Summary Conventional wisdom holds that radiation therapy is a physically targeted anti-cancer modality and that its cancer targets are genetically and biologically uniform....

Active NON-SBIR/STTR RPGS
Implementing the NYU Electronic Patient Visit Assessment (ePVA) for Head and Neck Cancer In Rural and Urban Populations
NATIONAL CANCER INSTITUTE University of Texas Hlth Sci Ctr Houston United States 2023 – 2028

ABSTRACT Approximately 66,000 individuals will be diagnosed with head and neck cancer (HNC) in the United States (US) in 2022. Most patients with HNC are treated aggressively with...

$6.44M
USD
Active NON-SBIR/STTR RPGS
Alpha-emitter Imaging for Dosimetry and Treatment Planning
NATIONAL CANCER INSTITUTE Johns Hopkins University United States 2023 – 2028

Radiopharmaceutical therapy with α-particle emitters (αRPT) is a highly effective cancer therapy modality; it delivers potent alpha-particle radiation to cancer cells and is theref...

Active RESEARCH CENTERS
Research Project 2: Neuroblastoma
NATIONAL CANCER INSTITUTE Dana-Farber Cancer Inst United States 2023 – 2028

Project Summary Radiopharmaceuticals have shown tremendous clinical promise, resulting in regulatory approvals of several agents. Such targeted radiotherapy exposes tumor cells to...

Active NON-SBIR/STTR RPGS
Microscale Radionuclide S-values for αRPT
NATIONAL CANCER INSTITUTE Johns Hopkins University United States 2023 – 2028

Abstract / Summary – Project 2 Radiopharmaceuticals labeled with alpha-particle emitters (RPT) uniquely satisfy various conditions for therapy of cancer in its advanced stages. Al...

Active RESEARCH CENTERS
Shared Resource Core 1: Molecular Data Science and Advanced Dosimetry
NATIONAL CANCER INSTITUTE Dana-Farber Cancer Inst United States 2023 – 2028

PROJECT SUMMARY The convergence of radiation oncology, cancer genomics, data science, computational modeling, and artificial intelligence presents spectacular opportunities and cha...

Active OTHER RESEARCH-RELATED
Dissecting the role of DNA damage repair deficiency in Ewing sarcoma pathogenesis for improved risk stratification and treatment
NATIONAL CANCER INSTITUTE Dana-Farber Cancer Inst United States 2023 – 2028

PROJECT SUMMARY Ewing sarcoma is the second most common bone and soft tissue cancer impacting children and adolescents worldwide. It is an aggressive malignancy requiring multimoda...

$1.63M
USD
Active NON-SBIR/STTR RPGS
Macro-to-micro (M2µ) Activity Apportionment for αRPT
NATIONAL CANCER INSTITUTE Johns Hopkins University United States 2023 – 2028

Recent advances in the targeted delivery of radionuclides and the increased availability of -emitters appropriate for clinical use have led to patient trials of multiple α-emitter...

Active RESEARCH CENTERS
Shared Resource Core 2: Clinical Artificial Intelligence Core
NATIONAL CANCER INSTITUTE Dana-Farber Cancer Inst United States 2023 – 2028

PROJECT SUMMARY Artificial intelligence (AI) algorithms have the potential to fundamentally change medicine through their ability to recognize complex patterns in medical data. The...

Active RESEARCH CENTERS
Cross-Training Core (ROBIN-NEST)
NATIONAL CANCER INSTITUTE Dana-Farber Cancer Inst United States 2023 – 2028

PROJECT SUMMARY Education and training in the radiation medicine sciences are frequently compartmentalized along specific well- worn paths with only superficial attention given to...

Completed SBIR-STTR RPGS
Process Development and Preclinical Advancement of a Novel Nanoparticle Formulation for Immune Activation
NATIONAL CANCER INSTITUTE Saros Therapeutics Inc United States 2023 – 2025

Summary Despite the success of immune checkpoint inhibitors for some types of cancer, the overall response rate remains suboptimal. The majority of solid tumors exclude T-cells (te...

$8.5M
USD
Active NON-SBIR/STTR RPGS
Radiobioeffect Modeling of αRPT
NATIONAL CANCER INSTITUTE Johns Hopkins University United States 2023 – 2028

If absorbed dose is to be used in treatment-planning based α-particle emitter radiopharmaceutical therapy (αRPT), the impact of DNA double-strand break (DSB) repair status- the pro...

Active NON-SBIR/STTR RPGS
Administrative
NATIONAL CANCER INSTITUTE Johns Hopkins University United States 2023 – 2028

Project Summary The Administrative Core is responsible for the managerial oversight of the P01. This includes all administrative and budgetary matters, scheduling advisory committe...

Active NON-SBIR/STTR RPGS
Core 1: Animal Models, Pathology and Tissue
NATIONAL CANCER INSTITUTE Johns Hopkins University United States 2023 – 2028

Project Summary Alpha-particle -emitter radiopharmaceutical therapy (αRPT) is a new and rapidly evolving therapeutic modality that can deliver highly potent, alpha-particles to dis...

Active RESEARCH CENTERS
The Empilisweni Center for Women's Health - Advancing Implementation of Equitable Cervical Cancer Control
NATIONAL CANCER INSTITUTE Columbia University Health Sciences United States 2023 – 2028

Abstract (Overall). Cervical cancer is a leading cause of cancer-related deaths among women in low- and middle-income countries (LMICs), and it is almost entirely preventable.1,2-4...

$10.68M
USD
Active NON-SBIR/STTR RPGS
Core 2: Biostatistics
NATIONAL CANCER INSTITUTE Johns Hopkins University United States 2023 – 2028

Project Summary The Biostatistics Core (Core C) will collaborate and provide comprehensive statistics service and infrastructure support for clinical and pre-clinical studies to al...

Active NON-SBIR/STTR RPGS
Core 3: Patient Data
NATIONAL CANCER INSTITUTE Johns Hopkins University United States 2023 – 2028

Project Summary Overall, the primary effort of this Core will be to conduct a master imaging trial for patients undergoing RPT treatment at Johns Hopkins, as well as to establish d...

Active NON-SBIR/STTR RPGS
Dissecting the Determinants of IDH-mutant Gliomas Response to Mutant IDH Inhibitors
NATIONAL CANCER INSTITUTE Massachusetts General Hospital United States 2023 – 2028

Abstract This proposal focuses on IDH-mutant gliomas, a leading cause of cancer-related death in people under 45-years old. IDH mutations result in profound distortions in metaboli...

$6.53M
USD
Active RESEARCH CENTERS
Administrative and Engagement Core
NATIONAL CANCER INSTITUTE Columbia University Health Sciences United States 2023 – 2028

Our investigator team at Columbia University and the University of Cape Town, through a nearly thirty-year collaboration under the Khayelitsha Cervical Cancer Screening Program (KC...